文献速递白血病

研究儿童白血病增殖细胞对BCL-2抑制剂的反应

Investigating the response of paediatric leukaemia-propagating cells to BCL-2 inhibitors.
PubMed 文献 · Br J Haematol · 2020-05-25

该研究在体外和体内比较了BCL-2抑制剂navitoclax与venetoclax对儿童B细胞前体(BCP)和T细胞急性淋巴细胞白血病(ALL)白血病增殖细胞(LPC)亚群的作用,并对比BCL-2表达水平。体外两药对多数BCP-ALL LPC有效,但CD34-/CD19-细胞例外;T-ALL仅navitoclax有效,CD34-/CD7- LPC对两药均耐药。体内navitoclax较venetoclax更有效,显著改善移植小鼠生存;venetoclax对T-ALL体内效果不佳。治疗后耐药亚群比例显著增加,其促凋亡BCL-2基因表达较低,可能解释敏感性缺乏。

要点

  • 体外两药对多数BCP-ALL LPC有效,但CD34-/CD19-细胞例外。
  • T-ALL中仅navitoclax体外有效,CD34-/CD7- LPC对两药均耐药。
  • 体内navitoclax较venetoclax更有效,显著改善移植小鼠生存。

核心结论

  • 部分LPC对BCL-2抑制剂耐药,持续缓解需将其与其他治疗联合使用。

研究设计与样本

  • 在体外和体内对BCP-ALL和T-ALL病例的LPC亚群直接比较navitoclax与venetoclax,并与微阵列分析和Western blotting检测的BCL-2水平对比。

主要发现

  • 体外两药对多数BCP-ALL LPC有效,但CD34-/CD19-细胞例外。
  • 体外T-ALL仅navitoclax有效,CD34-/CD7- LPC对两药均耐药。
  • 体内navitoclax较venetoclax更有效,显著改善移植BCP-和T-ALL样本小鼠的生存。
  • 体内venetoclax对T-ALL病例效果不佳。
  • 体内治疗后CD34+/CD19-、CD34-/CD19- BCP-ALL细胞和CD34-/CD7- T-ALL细胞比例显著增加,这些亚群促凋亡BCL-2基因表达较低。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Relapse of paediatric acute lymphoblastic leukaemia (ALL) may occur due to persistence of resistant cells with leukaemia-propagating ability (LPC). In leukaemia, the balance of B-cell lymphoma-2 (BCL-2) family proteins is disrupted, promoting survival of malignant cells and possibly LPC. A direct comparison of BCL-2 inhibitors, navitoclax and venetoclax, was undertaken on LPC subpopulations from B-cell precursor (BCP) and T-cell ALL (T-ALL) cases in vitro and in vivo. Responses were compared to BCL-2 levels detected by microarray analyses and Western blotting. In vitro, both drugs were effective against most BCP-ALL LPC, except CD34- /CD19- cells. In contrast, only navitoclax was effective in T-ALL and CD34- /CD7- LPC were resistant to both drugs. In vivo, navitoclax was more effective than venetoclax, significantly improving survival of mice engrafted with BCP- and T-ALL samples. Venetoclax was not particularly effective against T-ALL cases in vivo. The proportions of CD34+ /CD19- , CD34- /CD19- BCP-ALL cells and CD34- /CD7- T-ALL cells increased significantly following in vivo treatment. Expression of pro-apoptotic BCL-2 genes was lower in these subpopulations, which may explain the lack of sensitivity. These data demonstrate that some LPC were resistant to BCL-2 inhibitors and sustained remission will require their use in combination with other therapeutics.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Diamanti P, Ede BC, Dace PE, et al. Investigating the response of paediatric leukaemia-propagating cells to BCL-2 inhibitors. Br J Haematol. 2020. PMID: 32452017. doi:10.1111/bjh.16773

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。